| Title | Integration between MCL1 gene co-expression module and the RISS enables precise prognostication and prediction of response to proteasome inhibitor-based therapy in individual multiple myeloma |
|---|---|
| Description | We recently identified a gene module of 87 genes co-expressed with MCL1 (MCL1-M), a critical regulator of plasma cell survival. MCL1-M captures both MM cell-intrinsically acting signals and the signals regulating the interaction between MM cells with bone marrow microenvironment. MM can be clustered into MCL1-M high and MCL1-M low subtypes. While the MCL1-M high MMs are enriched in a preplasmablast signature, the MCL1-M low MMs are enriched in B cell-specific genes. In multiple independent datasets, MCL1-M high MMs exhibited poorer prognosis compared to MCL1-M low MMs. Re-analysis of the phase III HOVON-65/GMMG-HD4 showed that only MCL1-M MMs, but not MCL1-M low MMs, benefited from bortezomib-based treatment. To translate the MCL1-M clustering scheme into a platform for individual diagnosis, we refined the classifier genes and developed a support vector machine-based algorithm. |
| Organism | Homo sapiens |
| Data Type | Transcriptomic |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA009519 |
| Release Date | 2024-03-26 |
| Submitter | Yin Wu (wudxuan@126.com) |
| Organization | Beijing Chaoyang Hospital, Capital Medical University |
| Submission Date | 2022-05-14 |
The data cannot be downloaded as it has not yet been registered in the Human Genetic Resource Management Platform of MOST.
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download |
|---|---|---|---|---|---|---|
| OMIX001137-20-01 | CY_BACTH_NO-USE2 | 1 | Transcriptomic | 52.9 MB | csv | Unavailable |
| Paper Title | Journal Name | Publish Time | Accession | Citing Type |
|---|---|---|---|---|
| Plasma cell development-based prediction of prognosis and treatment response in individual multiple myeloma | Frontiers of Medicine | 2025-12 | OMIX001137 | Deposit |
| Distinct Pathway Activities are Associated with Prognosis and Response to Bortezomib- containing Treatment in MCL1-M Based Molecular Subtypes of Multiple Myeloma | Research Square | 2024-02 | OMIX001137 | Deposit |